Herpes Zoster Treatment Market Introduction and Overview
According to SPER Market Research, the Global Herpes Zoster Treatment Market is estimated to reach USD 337.48 million by 2032 with a CAGR of 3.61%.
The report includes an in-depth analysis of the Global Herpes Zoster Treatment Market, including market size and trends, product mix, applications, and supplier analysis. The varicella-zoster virus causes herpes zoster, also known as shingles, a common viral infection of the nerves that causes a painful rash of tiny blisters on a strip of skin anywhere on the body. The pain may last for months after the rash goes away. Shingles is more common in older adults over 50 and those with weakened immune systems. In youngsters, it is quite uncommon, and the symptoms are not as severe as they may be in an adult. Herpes zoster infection results from the virus lying dormant in specific nerves for years after a person has had chicken pox. The sporadic disease herpes zoster is thought to have a 10% to 20% lifetime incidence.
- December 2022; The Food and Drug Administration of the Philippines has approved the clinical study for Jiangsu Recbio Technology Co., Ltd.'s innovative adjuvanted recombinant shingles vaccine, REC610.
- September 2022; The US Food and Drug Administration has given Zydus Lifesciences approval to sell Pregabalin extended-release pills, which are used to treat pain brought on by nerve damage from shingles (herpes zoster) infections or diabetes.
Market Opportunities and Challenges
The market for herpes zoster infection treatments is expected to develop due to several factors, including an aging population that is also seeing an increase in herpes zoster cases, greater knowledge of the varicella vaccine's benefits, and an expansion of immunization programs worldwide. Additionally, aged persons are more prone to herpes zoster because of weakened immune systems. Nonetheless, the lack of qualified workers is anticipated to impede market expansion. On the other hand, a rise in medication development offers profitable prospects for market expansion.
The elderly population is an intensive care population, and the onset of viral diseases like Herpes zoster increases the risk of associated infections and other reactions. As a result, the adverse effects of anti-viral therapy treatment among this population present a major challenge to the market's growth. Further challenging the varicella zoster infection treatment market may be the availability of alternative therapy options for treating herpes zoster and varicella, such as homeopathy, vitamins, and other natural herbal treatments. A clinical investigation conducted in China also showed that the topical cream plus the modified Gentiana recipe worked better than antiviral medication for treating post-herpetic neuralgia.
Market Competitive Landscape
The competitive landscape of the worldwide herpes treatment market includes information by competitor. In-depth information is provided about the company's background, finances, revenue, market potential, R&D spending, new market initiatives, global reach, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product breadth and width, and application dominance. Only the companies' focus on the global market for herpes treatment is indicated by the data points above. Key corporate restructuring market players are Abbott Laboratory, Bausch Health, Cipla Inc, Camber Pharmaceuticals, GlaxoSmithKline plc, Merck & Co, Novartis AG. Pfizer Inc, Eli Lilly and Co, Teva Pharmaceutical Industries Ltd.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2032 |
| Base year considered | 2021 |
| Forecast period | 2022-2032 |
| Segments covered | By Treatment Type, By Route of Administration, By Distribution Channel |
| Regions covered | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Companies Covered | Abbott Laboratory, Bausch Health, Cipla Inc, Camber Pharmaceuticals, GlaxoSmithKline plc, Merck & Co, Novartis AG, Pfizer Inc, Eli Lilly and Co, Teva Pharmaceutical Industries Ltd
|
COVID-19 Impact on Global Herpes Zoster Treatment Market
The COVID-19 pandemic was said to have had a negative overall effect on the market for herpes zoster treatments. This was ascribed to elements including the challenge of managing the diagnosis and treatment of herpes zoster, which necessitates hospitalization, the protracted recuperation period associated with COVID-19, and treatment delays. Nonetheless, with the COVID-19 pandemic, this influence is anticipated to alter and spur market expansion. In addition, the number of people visiting hospitals for illnesses other than COVID-19 decreased due to a decline in surgeries and a decrease in patient visits as a result of shifting healthcare priorities and preventative measures to avoid getting the disease.
Key Target Audience
- Adults aged 50 and over
- Healthcare professionals (HCPs)
- Immunocompromised individuals
- People with chronic health conditions
- Government agencies
- Non-profit organizations
- Pharmaceutical companies
- Vaccine manufacturers
- Diagnostic test manufacturers
- Medical device companies
Our in-depth analysis of the Herpes Zoster Treatment Market includes the following segments:
| By Treatment Type: | Antiviral MedicationsAnti-inflammatoryMedicationsOthers |
| By Route of Administration: | OralTopical |
| By Distribution Channel: | Hospital PharmaciesDrug Stores & Retail PharmaciesOnline Providers |
Key Topics Covered in the Report
- Global Herpes Zoster Treatment Market Size (FY’2022-FY’2032)
- Overview of Global Herpes Zoster Treatment Market
- Segmentation of Global Herpes Zoster Treatment Market By Treatment Type (Antiviral Medications, Anti-inflammatory, Medications, Others)
- Segmentation of Global Herpes Zoster Treatment Market By Route of Administration (Oral, Topical)
- Segmentation of Global Herpes Zoster Treatment Market By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Providers)
- Statistical Snap of Global Herpes Zoster Treatment Market
- Expansion Analysis of Global Herpes Zoster Treatment Market
- Problems and Obstacles in Global Herpes Zoster Treatment Market
- Competitive Landscape in the Global Herpes Zoster Treatment Market
- Impact of COVID-19 and Demonetization on Global Herpes Zoster Treatment Market
- Details on Current Investment in Global Herpes Zoster Treatment Market
- Competitive Analysis of Global Herpes Zoster Treatment Market
- Prominent Players in the Global Herpes Zoster Treatment Market
- SWOT Analysis of Global Herpes Zoster Treatment Market
- Global Herpes Zoster Treatment Market Future Outlook and Projections (FY’2022-FY’2032)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Global Herpes Zoster Treatment Market
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Herpes Zoster Treatment Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Herpes Zoster Treatment Market
7. Global Herpes Zoster Treatment Market, By Treatment Type (USD Million) 2019-2032
7.1. Global Herpes Zoster Treatment Market Size, Share and Forecast, By Treatment Type, 2019-2025
7.2. Global Herpes Zoster Treatment Market Size, Share and Forecast, By Treatment Type, 2026-2032
7.3. Antiviral Medications
7.4. Anti-inflammatory
7.5. Medications
7.6. Others
8. Global Herpes Zoster Treatment Market, By Route of Administration (USD Million) 2019-2032
8.1. Global Herpes Zoster Treatment Market Size, Share and Forecast, By Route of Administration, 2019-2025
8.2. Global Herpes Zoster Treatment Market Size, Share and Forecast, By Route of Administration, 2026-2032
8.3. Oral
8.4. Topical
9. Global Herpes Zoster Treatment Market, By Distribution Channel (USD Million) 2019-2032
9.1. Global Herpes Zoster Treatment Market Size, Share and Forecast, By Distribution Channel, 2019-2025
9.2. Global Herpes Zoster Treatment Market Size, Share and Forecast, By Distribution Channel, 2026-2032
9.3. Hospital Pharmacies
9.4. Drug Stores & Retail Pharmacies
9.5. Online Providers
10. Global Herpes Zoster Treatment Market Forecast, 2019-2032 (USD Million)
10.1. Global Herpes Zoster Treatment Market Size and Market Share
11. Global Herpes Zoster Treatment Market, By Region, 2019-2032 (USD Million)
11.1. Global Herpes Zoster Treatment Market Size and Market Share By Region (2019-2025)
11.2. Global Herpes Zoster Treatment Market Size and Market Share By Region (2026-2032)
11.3. Asia-Pacific
11.3.1. Australia
11.3.2. China
11.3.3. India
11.3.4. Japan
11.3.5. South Korea
11.3.6. Rest of Asia-Pacific
11.4. Europe
11.4.1. France
11.4.2. Germany
11.4.3. Italy
11.4.4. Spain
11.4.5. United Kingdom
11.4.6. Rest of Europe
11.5. Middle East and Africa
11.5.1. Kingdom of Saudi Arabia
11.5.2. United Arab Emirates
11.5.3. Qatar
11.5.4. South Africa
11.5.5. Egypt
11.5.6. Morocco
11.5.7. Nigeria
11.5.8. Rest of Middle East & Africa
11.6. North America
11.6.1. Canada
11.6.2. Mexico
11.6.3. United States
11.7. Latin America
11.7.1. Argentina
11.7.2. Brazil
11.7.3. Rest of Latin America
12. Company Profile
12.1. Abbott Laboratory
12.1.1. Company details
12.1.2. Financial outlook
12.1.3. Product summary
12.1.4. Recent developments
12.2. Bausch Health
12.2.1. Company details
12.2.2. Financial outlook
12.2.3. Product summary
12.2.4. Recent developments
12.3. Cipla Inc.
12.3.1. Company details
12.3.2. Financial outlook
12.3.3. Product summary
12.3.4. Recent developments
12.4. Camber Pharmaceuticals.
12.4.1. Company details
12.4.2. Financial outlook
12.4.3. Product summary
12.4.4. Recent developments
12.5. GlaxoSmithKline plc.
12.5.1. Company details
12.5.2. Financial outlook
12.5.3. Product summary
12.5.4. Recent developments
12.6. Merck & Co.,
12.6.1. Company details
12.6.2. Financial outlook
12.6.3. Product summary
12.6.4. Recent developments
12.7. Novartis AG.
12.7.1. Company details
12.7.2. Financial outlook
12.7.3. Product summary
12.7.4. Recent developments
12.8. Pfizer Inc.
12.8.1. Company details
12.8.2. Financial outlook
12.8.3. Product summary
12.8.4. Recent developments
12.9. Eli Lilly and Co.
12.9.1. Company details
12.9.2. Financial outlook
12.9.3. Product summary
12.9.4. Recent developments
12.10. Teva Pharmaceutical Industries Ltd.
12.10.1. Company details
12.10.2. Financial outlook
12.10.3. Product summary
12.10.4. Recent developments
12.11. Others
13. Conclusion
14. List of Abbreviations
15. Reference Links